At the intersection of functional genomics, complex traits genetics, and statistical genetics, our primary research interest is in developing and extending methods for elucidating the genetic architecture of complex diseases and pharmacologic phenotypes. An ongoing project (Genotype-Tissue Expression [GTEx]) involves understanding the effects of genome variation on gene regulation and utilizing information on expression quantitative trait loci (eQTLs) to expand on genetic association studies. I also work on integrating large-scale DNA biobank data and electronic medical records to enhance research in (and the translational utility of) genetics and genomics. I have been a member of several consortia/groups, including the Type 2 Diabetes (T2D) Genetic Exploration by Next-generation Sequencing in Ethnic Samples (T2D-GENES) Consortium, the International Warfarin Pharmacogenetics Consortium – Genome Wide Association Studies (IWPC-GWAS), and the Pharmacogenomics of Anticancer Agents Research (PAAR) Group. I study the genetic, molecular, and environmental factors contributing to variation in cancer risk, response to therapy, and toxicity. I am particularly interested in understanding the genetic contribution to health disparities, in translating genomic information into disease risk prediction, and in extending the translational benefits of genomic research to at-risk populations in which health disparities are a continuing medical concern.